We are live on ! Find out more
N

Nuveen Portfolio holdings

AUM $369B
1-Year Est. Return 31.66%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$258B
AUM Growth
+$11.2B
Cap. Flow
-$8.74B
Cap. Flow %
-3.39%
Top 10 Hldgs %
19.2%
Holding
3,329
New
40
Increased
1,011
Reduced
1,986
Closed
159

Top Buys

Rank Stock Value
1
PLD icon
Prologis
PLD
+$352M
2
MRK icon
Merck
MRK
+$333M
3
NVDA icon
NVIDIA
NVDA
+$306M
4
TEAM icon
Atlassian
TEAM
+$280M
5
CTVA icon
Corteva
CTVA
+$253M

Sector Composition

Rank Sector Weight
1 Technology 22.56%
2 Healthcare 14.16%
3 Financials 12.95%
4 Consumer Discretionary 9.76%
5 Industrials 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SCOR icon
3026
Comscore
SCOR
$109M
$159K ﹤0.01%
6,846
TTCF
3027
DELISTED
Tattooed Chef, Inc Class A Common Stock
TTCF
$155K ﹤0.01%
126,514
-7,619
-6% -$22.6K
KLR
3028
DELISTED
Kaleyra, Inc.
KLR
$154K ﹤0.01%
58,056
+151
+0.3% +$502
RLYB icon
3029
Rallybio
RLYB
$85.8M
$150K ﹤0.01%
2,853
+52
+2% +$3.07K
DIBS icon
3030
1stdibs.com
DIBS
$171M
$148K ﹤0.01%
29,224
-20,697
-41% -$125K
SBT
3031
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
$148K ﹤0.01%
24,286
-15,355
-39% -$96.2K
JNCE
3032
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$146K ﹤0.01%
131,385
+15,431
+13% +$22K
BGRY
3033
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
$145K ﹤0.01%
240,767
-11,617
-5% -$13K
ANTX icon
3034
AN2 Therapeutics
ANTX
$214M
$144K ﹤0.01%
+15,065
New +$202K
BKKT icon
3035
Bakkt Inc
BKKT
$337M
$143K ﹤0.01%
4,826
-226
-4% -$10.5K
TYRA icon
3036
Tyra Biosciences
TYRA
$1.58B
$143K ﹤0.01%
18,756
NBP
3037
NovaBridge Biosciences American Depositary Shares
NBP
$202M
$140K ﹤0.01%
33,500
-38,700
-54% -$147K
ONDS icon
3038
Ondas Inc
ONDS
$5.19B
$138K ﹤0.01%
86,784
+12,660
+17% +$37.2K
CYD icon
3039
China Yuchai International
CYD
$1.78B
$135K ﹤0.01%
19,053
-2,553
-12% -$18.6K
WGS icon
3040
GeneDx Holdings
WGS
$2.3B
$134K ﹤0.01%
15,423
-5,633
-27% -$124K
PRTH icon
3041
Priority Technology Holdings
PRTH
$444M
$132K ﹤0.01%
25,156
VEL icon
3042
Velocity Financial
VEL
$729M
$132K ﹤0.01%
13,636
PEAR
3043
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$132K ﹤0.01%
112,135
+15,904
+17% +$33.4K
SCWX
3044
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
$129K ﹤0.01%
20,242
-12,503
-38% -$88.2K
LNAI
3045
Lunai Bioworks
LNAI
$10.9M
$128K ﹤0.01%
1,557
-207
-12% -$27.8K
CPSS icon
3046
Consumer Portfolio Services
CPSS
$206M
$127K ﹤0.01%
14,312
-11,485
-45% -$82.4K
JOAN
3047
DELISTED
JOANN, Inc. Common Stock
JOAN
$127K ﹤0.01%
44,704
LOCL icon
3048
Local Bounti
LOCL
$23.5M
$125K ﹤0.01%
6,920
+2,303
+50% +$71.8K
NL icon
3049
NLI Holdings
NL
$317M
$124K ﹤0.01%
18,196
-12,502
-41% -$93.2K
GRNA
3050
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
$123K ﹤0.01%
104,610
-50,620
-33% -$82.4K

Similar funds

Nuveen's Q4 2022 Portfolio in Review

As of Q4 2022, Nuveen held 3,329 positions worth $258B, up 4.5% from $247B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Nuveen withdrew a net $8.74B in Q4 2022, closing 159 positions and reducing 1,986 holdings. Its most notable exit was Twitter, Inc., an estimated $237M position sold in full.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Nuveen opened a new position in Atlassian worth $226M.

  • Nuveen's largest Q4 2022 buy was Atlassian: 1,759,716 shares worth $226M.
  • Nuveen added most to Prologis in Q4 2022, an estimated $352M increase.
  • Nuveen's biggest Q4 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $3.41B.
  • Nuveen fully exited Twitter, Inc. in Q4 2022, selling an estimated $237M.
  • Nuveen's ten largest holdings make up 19% of its $258B portfolio in Q4 2022.
  • Nuveen opened 40 new positions and closed 159 in Q4 2022.
  • Nuveen's portfolio value rose 4.5% quarter-over-quarter to $258B.

Based on Nuveen's 13F filing for Q4 2022, filed 14 Feb 2023.